HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
44 hedge funds and large institutions have $45.6M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 6 reducing their positions, and 9 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 6
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
13% more capital invested
Capital invested by funds: $40.5M → $45.6M (+$5.09M)
7% more funds holding
Funds holding: 41 → 44 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$6.12M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$1.2M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.09M |
| 4 |
SIM
Spark Investment Management
New York
|
+$738K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$723K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$1.03M |
| 2 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$684K |
| 3 |
VF
Virtu Financial
New York
|
-$284K |
| 4 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$239K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$130K |
HTGM Hedge Fund Activity: Q2 2018 in Review
44 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q2 2018, worth a combined $45.6M — up 13% from $40.5M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new HTGM positions and 9 closed out — a net gain of 4 holders — while 15 added to existing stakes and 6 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $6.12M. The largest seller was EAM Investors, exiting entirely with an estimated $1.03M sold.
- 44 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q2 2018, up from 41 in Q1 2018.
- Funds reported $45.6M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q2 2018, up 13% quarter-over-quarter.
- 13 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q2 2018 and 9 closed out, a net change of +4 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q2 2018 was Stonepine Capital Management, an estimated $6.12M added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q2 2018 was EAM Investors, an estimated $1.03M sold.
Based on aggregated 13F filings for Q2 2018.